These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

581 related items for PubMed ID: 8859190

  • 1. Immunohistochemical analysis of proliferating cell nuclear antigen, p53 protein and nm23 protein, and nuclear DNA content in transitional cell carcinoma of the bladder.
    Shiina H, Igawa M, Nagami H, Yagi H, Urakami S, Yoneda T, Shirakawa H, Ishibe T, Kawanishi M.
    Cancer; 1996 Oct 15; 78(8):1762-74. PubMed ID: 8859190
    [Abstract] [Full Text] [Related]

  • 2. Relationship of genetic instability with immunoreactivities for p53 protein and proliferating cell nuclear antigen in transitional cell carcinoma of the bladder.
    Shiina H, Igawa M, Yagi H, Urakami S, Shirakawa H, Ishibe T.
    Eur Urol; 1996 Oct 15; 30(1):80-8. PubMed ID: 8854073
    [Abstract] [Full Text] [Related]

  • 3. Immunohistochemical analysis of nm23 protein in transitional cell carcinoma of the bladder.
    Shiina H, Igawa M, Urakami S, Shirakawa H, Ishibe T.
    Br J Urol; 1995 Dec 15; 76(6):708-13. PubMed ID: 8535713
    [Abstract] [Full Text] [Related]

  • 4. Immunohistochemical analysis of bcl-2 expression in transitional cell carcinoma of the bladder.
    Shiina H, Igawa M, Urakami S, Honda S, Shirakawa H, Ishibe T.
    J Clin Pathol; 1996 May 15; 49(5):395-9. PubMed ID: 8707954
    [Abstract] [Full Text] [Related]

  • 5. Biological characteristics of inverted papilloma of the urinary bladder.
    Urakami S, Igawa M, Shirakawa H, Shiina H, Ishibe T.
    Br J Urol; 1996 Jan 15; 77(1):55-60. PubMed ID: 8653317
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Clinical significance of immunohistochemically detectable p53 protein in renal cell carcinoma.
    Shiina H, Igawa M, Urakami S, Shirakawa H, Ishibe T, Kawanishi M.
    Eur Urol; 1997 Jan 15; 31(1):73-80. PubMed ID: 9032539
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Nm23-H1 protein, DNA-ploidy and S-phase fraction in relation to overall survival and disease free survival in transitional cell carcinoma of the bladder.
    Alderisio M, Cenci M, Valli C, Russo A, Bazan V, Dardanoni G, Cucciarre S, Carreca I, Macaluso MP, Tomasino RM, Vecchione A.
    Anticancer Res; 1998 Jan 15; 18(6A):4225-30. PubMed ID: 9891471
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. PCNA and p53 in urinary bladder cancer: correlation with histological findings and prognosis.
    Inagaki T, Ebisuno S, Uekado Y, Hirano A, Hiroi A, Shinka T, Ohkawa T.
    Int J Urol; 1997 Mar 15; 4(2):172-7. PubMed ID: 9179692
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Relationship of serum testosterone level with proliferating cell nuclear antigen and nm23 protein in human prostatic carcinoma tissue.
    Shiina H, Igawa M, Shigeno K, Wada Y, Yoneda T, Yagi H, Shirakawa R, Nagasaki M.
    Oncology; 1997 Mar 15; 54(6):482-9. PubMed ID: 9394845
    [Abstract] [Full Text] [Related]

  • 15. Immunohistochemical analysis of p53 and proliferating cell nuclear antigen (PCNA) in bladder cancer: positive immunostaining and radiosensitivity.
    Ogura K, Habuchi T, Yamada H, Ogawa O, Yoshida O.
    Int J Urol; 1995 Nov 15; 2(5):302-8. PubMed ID: 8749948
    [Abstract] [Full Text] [Related]

  • 16. DNA content and proliferation activity in superficial transitional cell carcinoma of the bladder.
    Pantazopoulos D, Ioakim-Liossi A, Karakitsos P, Aroni K, Kakoliris S, Kanavaros P, Kyrkou KA.
    Anticancer Res; 1997 Nov 15; 17(1B):781-6. PubMed ID: 9066620
    [Abstract] [Full Text] [Related]

  • 17. Expression of the cyclin-dependent kinase inhibitor p27 in transitional cell bladder cancers: is it a good predictor for tumor behavior?
    Doganay L, Altaner S, Bilgi S, Kaya E, Ekuklu G, Kutlu K.
    Int Urol Nephrol; 2003 Nov 15; 35(2):181-8. PubMed ID: 15072490
    [Abstract] [Full Text] [Related]

  • 18. Clinical significance of mdm2 and p53 expression in bladder cancer. A comparison with cell proliferation and apoptosis.
    Shiina H, Igawa M, Shigeno K, Yamasaki Y, Urakami S, Yoneda T, Wada Y, Honda S, Nagasaki M.
    Oncology; 1999 Apr 15; 56(3):239-47. PubMed ID: 10202280
    [Abstract] [Full Text] [Related]

  • 19. The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer.
    Korkolopoulou P, Christodoulou P, Kapralos P, Exarchakos M, Bisbiroula A, Hadjiyannakis M, Georgountzos C, Thomas-Tsagli E.
    Pathol Res Pract; 1997 Apr 15; 193(11-12):767-75. PubMed ID: 9521509
    [Abstract] [Full Text] [Related]

  • 20. Accumulation of nuclear p53 and tumor progression in bladder cancer.
    Esrig D, Elmajian D, Groshen S, Freeman JA, Stein JP, Chen SC, Nichols PW, Skinner DG, Jones PA, Cote RJ.
    N Engl J Med; 1994 Nov 10; 331(19):1259-64. PubMed ID: 7935683
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.